Using a monoclonal antibody directed against the primate nerve growth factor (NGF) receptor, we examined the expression of NGF receptors within neuronal perikarya of normal adult human cerebral cortex (27-98 years old) and individuals with Alzheimer disease (AD). This expression of cortical NGF receptors was compared with that seen in other neurological diseases and normal human development as well as in young and aged nonhuman primates. NGF receptorcontaining cortical neurons were not observed in young adults (<50 years old) and were observed only infrequently in nondemented elderly individuals (50-80 years old). In contrast, numerous NGF receptor-containing cortical neurons were seen in AD patients of all ages and in one 98-year-old nondemented patient. In advanced age and AD, numerous NGF receptorpositive neurons were located within laminae Il-VI of temporal association cortices whereas only a few were seen in the subicular complex, entorhinal cortex, parahippocampal gyrus, and amygdaloid complex. These perikarya appeared healthy, with bipolar, fusiform, or multipolar morphologies and extended varicose dendritic arbors. These neurons failed to express neurofibrillary tangle-bearing material. In contrast to AD, NGF receptor-containing cortical neurons were not observed in Parkinson disease, Pick disease, or Shy-Drager syndrome. The NGF receptor-containing cortical neurons seen in advanced age and AD were similar in morphology to those observed in human fetal cortex. No NGF receptor-containing cortical neurons were observed in young or aged nonhuman primates. These rmdings suggest that neurons within the human cerebral cortex exhibit plasticity in their expression of NGF receptors in AD and extreme advanced aging.
Only limited examples of neural plasticity and reorganization have been demonstrated in the aged human brain. For instance, cortical neurons increase dendritic length as a function of age, an effect not seen in Alzheimer disease (AD) (1) . In AD, hippocampal sprouting of acetylcholinesterasecontaining fibers occurs (2) and galanin-containing interneurons hyperinnervate magnocellular cholinergic basal forebrain neurons (3) . It is possible that neurotrophic factors such as nerve growth factor (NGF) mediate some aspects of plasticity in aging and disease.
In the normal adult brain, NGF has been implicated in the maintenance and survival of cholinergic neurons within the basal forebrain (4, 5) , a cell group consistently impaired in AD (6, 7) . In both the peripheral and the central nervous system (CNS) the effects of NGF are mediated by interactions with specific receptors present on the surface of NGFresponsive neurons (8) (9) (10) (11) (12) (13) (14) . Much of the interest in NGF has been fueled by the suggestion that treatment with NGF may therapeutically benefit patients with AD by slowing or preventing the degenerative events underlying the loss of essential NGF receptor (NGFR)-containing cells (15) . More recently, immunocytochemical and in situ hybridization experiments have shown that noncholinergic brain regions (e.g., hypothalamic pituitary axis and cerebellum) also express receptors for NGF (16) (17) (18) (19) (20) , suggesting that the NGF/NGFR system may have more widespread actions within the CNS than originally believed.
Like other CNS receptor systems, NGFR expression is not static but can be up-or downregulated in accord with endogenous or experimentally induced alterations in the environmental milieu. For instance, developmental investigations suggest that there is a transitory expression of NGFRs prenatally within the rodent cerebral cortex (21) . This expression, along with a concomitant accumulation of NGF, may play a crucial role in guiding cortical neuronal and afferent fiber development (21, 22) . Cortical neurons do not express NGFRs postnatally (e.g., refs. 12 and 13). However, NGF levels in situ can influence the expression of central NGFRs (23) . Infusion of NGF into the rodent striatum results in a reexpression of NGFR-immunoreactive neurons within cholinergic striatal neurons (24) similar to that observed during development (25) (26) (27) . Furthermore, intraventricular infusion of NGF in rodents and primates increases the number of NGFR-immunoreactive neurons within the lumbar spinal cord (28) . Damage to both central and peripheral neurons also induces the novel postnatal expression of NGFRs (29) (30) (31) . Therefore it is possible that neural damage may upregulate NGF production, resulting in an overexpression of NGFRs (8, 32) . This would be consistent with previous observations that neurotrophic factors accumulate in CNS wounds (33) and that both NGF-like and non-NGF-like factors appear to be involved in such responses (24 for Pick disease, and 4.7 + 0.73 hr for normal controls. All brains were processed according to published protocols (11-13, 15, 16, 32-35) . Briefly, brains were sliced transversely into 10-mm slabs with a calibrated brain slice apparatus. Each slab was hemisected; the right hemisphere was fixed by immersion in 4% paraformaldehyde in phosphate buffer (pH 7.4) for 24 hr at 40C and cryoprotected as described (34) . Tissue blocks were cut on a sliding knife microtome (40 ,um) , and sections through the amygdaloid complex, hippocampus proper, subicular complex, and entorhinal cortex as well as the inferior, middle, and superior temporal cortices were analyzed. With thioflavin S and Bielschowsky silver stains (6, (35) (36) (37) , normal controls revealed only an occasional neuritic plaque (NP) and neurofibrillary tangle (NFT). The clinical diagnosis of AD was confirmed histopathologically according to the multifocal distribution of NPs and NFTs (38) as defined by the ageadjusted guidelines of the National Institute on Aging (39) . The diagnosis of Pick disease was confirmed by the presence of numerous cortical Pick bodies, and Parkinson disease was characterized by the presence of Lewy bodies, free neuromelanin, and extensive neuronal loss within the substantia nigra pars compacta. Clinically, the Shy-Drager case exhibited parkinsonism and autonomic insufficiency and upon postmortem analysis displayed neuropathology characteristic of Shy-Drager syndrome.
Fetal Human Tissue. To assess whether cortical neurons containing NGFRs in advanced aging or AD may be a reexpression of a normally occurring cortical developmental pattern (40-42), we also examined NGFR immunoreactivity in four human fetal brains (embryonic weeks 16, 19, 21, and 24). Each brain was immersion-fixed in 4% paraformaldehyde in phosphate buffer (pH 7.4) for 24 hr, cryoprotected in graded sucrose concentrations (10-40%), and cut frozen (40 ,um) in either the sagittal (week 16) or the coronal (weeks 19, 21 , and 24) plane.
Monkey Tissue. Series of coronal sections were examined through all four cortical lobes from two young (4 and 7 years old) and two aged (21 and 33 years) baboons (Papio anubis), one aged rhesus monkey (Macaca mulatta; 32 years), and 20 young adult cebus monkeys (Cebus apella; 4-10 years). Prior to sacrifice nonhuman primates were treated with ketamine (20 mg/kg, i.m.), deeply anesthetized with sodium pentobarbital (25 mg/kg, i.v.) and perfused transcardially with -500 ml of ice-cold 0.9% saline followed by fixation with 4% paraformaldehyde (pH 7.4). One cebus monkey brain was immersion-fixed with 4% paraformaldehyde. Each brain was removed from the calvaria, cryoprotected in 30%o sucrose/0. 1 M phosphate buffer, pH 7.4/0.9% NaCl, and cut (40 ,um) on a sliding knife microtome.
Immunocytochemistry. All human and nonhuman samples were identically immunoreacted for the visualization of the NGFR by using a monoclonal antibody (12, 13) as described (6, 12, 13, 16, (35) (36) (37) . Background staining was blocked with a 1-hr incubation in a Tris-buffered saline solution containing 3% normal horse serum, 2% bovine serum albumin, and 0.05% Triton X-100. After incubation with the NGFR primary antibody (1:60,000-80,000) for 48-72 hr at room temperature, sections were sequentially incubated with biotinylated horse anti-mouse IgG secondary antibody (1:100; Vector Laboratories) and the avidin-biotin complex (ABC Elite; 1:1000) for 60-75 min. Sections were reacted in a chromagen solution containing Tris-buffered saline, 2.5% NiSO4, 0.05% 3,3'-diaminobenzidine, and 0.005% H202. Selected sections were processed in an identical manner except that NiSO4 was omitted from the chromagen solution. Some of these sections were counterstained with thioflavin S as described (e.g., ref. 6). Controls consisted of tissue processed in an identical fashion except that the primary antibody solvent or an irrelevant IgG was employed in lieu of the primary antibody.
Sections were mounted on gelatin-coated slides, dehydrated, and coverslipped with Permount.
It is important to note that specificity for any immunocytochemical reaction product is not absolute. Regardless ofthe fact that vehicle substitution for the primary antibody or incubation in an irrelevant mouse IgG may abolish specific immunoreactivity, the potential for antisera to crossreact with structurally related antigens cannot be excluded. Thus a degree of caution is warranted and the term immunoreactivity in this study refers to "like" immunoreactivity.
RESULTS
Using either diaminobenzidine (brown reaction product) or metallic intensification (dark blue reaction product) as the chromogen, NGFR immunohistochemistry revealed numerous positive cortical neurons within limbic medial temporal lobe and adjacent ventral and lateral temporal neocortical association areas in each AD case (Fig. 1A) . These neurons were pleomorphic in appearance and exhibited a range of staining characteristics. Most were intensely immunoreactive, whereas others were lightly immunoreactive. Although it was most common to observe individual NGFR-expressing neurons within a particular cortical lamina, we also observed clusters or rows of these perikarya ( Fig. 2A) . The staining characteristics of the cortical NGFR-expressing neurons was similar to those previously described in the basal forebrain (11) (12) (13) (14) . Sections stained either with the primary antibody deleted or with an irrelevant IgG failed to display similar immunoreactivity in the cortex or the basal forebrain.
In AD sections, NGFR-containing cortical neurons were observed within the rostral portion of the temporal pole (Brodmann's area 38; ref. 43 ), the periamygdaloid cortex, and the inferior and middle temporal cortices (Brodmann's areas 20 and 21). For the most part, the immunostaining was most intense in a diverse population of small neurons scattered throughout layers II-VI as well as in an occasional cell body in the white matter. The primary neuronal type was multipolar or stellate and exhibited intensely stained perikarya and extensive proximal dendrites (Fig. 2 A-C cells demonstrated spines on their primary dendrites with varicose s( zondary and tertiary dendrites. Fusiform-type cells with two polar main dendrites were also found scattered throughout the cortex. Virtually no spines were seen along the dendrites of these cells, although we observed an occasional varicosity. A few bipolar-appearing neurons were also observed within the cortex. In contrast to the numerous cortical NGFR-immunoreactive neurons in temporal neocortex, the more ventromedially located entorhinal and perirhinal cortices, as well as the subicular complex, exhibited only a few immunoreactive neurons. In particular, the hippocampal formation was virtually devoid of any NGFR-containing perikarya, whereas the perirhinal regions contained several immunoreactive neurons. The amygdaloid complex contained scattered NGFR-immunoreactive neurons, mainly in the basolateral complex. Interestingly, the periamygdaloid cortex exhibited numerous immunostained perikarya with cellular morphologies similar to those seen in the temporal neocortex. Although an occasional dystrophic-appearing neuron was seen in the cortex, the vast majority of NGFRcontaining neurons appeared healthy. In fact, immunoreacted sections counterstained with thioflavin S for the visualization of NFT-bearing material failed to reveal dualstained cortical NGFR-positive neurons (Fig. 3A) . . l _ > a r .,li; r . . . . . immunoreactive cortical neuron was seen in older control cases (>50 years old). In contrast, numerous NGFRimmunoreactive neurons were seen in sections from a 98-year-old normal female ( Fig. 1A; Fig. 2 D-G) . Neuropathologic examination of this brain revealed no NPs or NFTs in any limbic or neocortical region examined. However, sections stained for NGFR immunoreactivity revealed numerous positive cortical neurons that were similar in morphology and location to those seen in AD. Most of the immunoreactive neurons were bipolar, multipolar, or stellate with intense perikaryal and extensive dendritic staining (e.g., Fig. 2C ). NGFR-positive neurons were found scattered throughout layers II-VI of Brodmann's areas 20, 21, and 38, with a preponderance of cells within the middle cortical laminae. The entorhinal and perirhinal cortex contained a few NGFRimmunoreactive neurons. In contrast, the hippocampus proper was virtually devoid of any cell staining. Interestingly, in this very old normal brain the basolateral amygdaloid complex and periamygdaloid cortex contained numerous NGFR-expressing neurons.
In each fetal specimen examined (16-24 weeks of gestation), numerous NGFR-immunoreactive neurons were observed within the neocortex and limbic cortex. Such neurons were rarely observed within the hippocampus and amygdaloid complex. These neurons were bipolar and multipolar with long beaded processes and were located preferentially throughout the developing cortical subplate zone (e.g., Fig.  3B ). While some of these neurons were morphologically similar to those seen in AD (compare Figs. 3B and 2C ), greater numbers of NGFR-containing cortical neurons were seen in the fetal specimens. In contrast, no specific immunoreactivity was seen in these specimens when sections were reacted without the primary antibody.
Although (40) (41) (42) .
The factors that mediate this novel cortical NGFR expression remain undefined. One candidate is the NGF protein. It is well established that NGF and its receptor have a "feedforward" relationship (5). Indeed, infusion of NGF into the striatum (24) or lateral ventricle (28) results in the expression of NGFR-immunoreactive neurons. It still remains to be determined whether NGF levels are altered in human aging or AD. If NGF levels are increased during some aspect of aging or disease process(es), a resulting (re)expression of NGFRs may occur. This phenomenon would potentially develop preferentially within the cortex, where endogenous levels of NGF are normally high (4). Indeed, normally high levels of endogenous NGF in cortex may provide a potent source of trophic support for those cortical neurons synthesizing receptors during extreme advanced aging and AD.
Whether this new population of NGFRs is responding to NGF or to other related trophic molecules is unclear. Both brain-derived neuronotrophic factor (BDNF; ref. 44 ) and neurotropin 3 (NT-3; refs. 45 and 46) display a striking structural homology with NGF and exhibit overlapping trophic activity. The NGFRs displayed by cortical neurons in advanced aging and AD potentially may bind NGF, BDNF, and NT-3 either alone or in combination in an attempt to mediate trophic support. Lastly, since the probes used in this study recognize the low-affinity NGFR (47) , it still needs to be determined whether physiologically active high-affinity NGFRs are also expressed within cortical neurons. This de novo expression of NGFRs within cortical neurons is among the first evidence of NGF-mediated trophism in advanced aging and AD (48) . This may represent plasticity by a select population of neurons that morphologically appear resistant to neurodegenerative changes in AD. Since NGF has been proposed as a therapeutic approach for the treatment of AD, this strategy may need to account for the potential effects of this growth factor upon these NGFR-containing cortical neurons.
